Table 1. Epstein-Barr virus humanized mouse studies.
| Mouse | Epstein-Barr virus
strain |
Year | Findings | References |
|---|---|---|---|---|
| NSG+CD34-depleted human
cord blood mononuclear cells |
M81 BAC and p2089
B95-8 LMP1-KO |
2016 | Blocking PD-1/CTLA-4 inhibits Epstein-Barr virus
(EBV)-induced lymphoma growth. |
67 |
| NSG+purified CD34-positive
cells from individual fetal liver samples |
GFP-EBV B95-8 WT | 2016 | Leukocytes lacking cognate HLA ligands interfere with
KIR + natural killer (NK) recognition of HLA- tumors but improve NK-mediated control of EBV infection. |
68 |
| NSG-A2tg (expressing
HLA -A2)+purified CD34-positive cells from two fetal liver samples |
M81BAC,
M81BACΔC1, M81BACΔC2, M81BACΔC1C2, M81BACΔb2, and M81BACΔAll |
2015 | BART microRNAs repress tumorigenesis
in vivo and
likely facilitate long-term persistence in the infected host. |
69 |
| Rag2
−/− γC
−/− double
knockout+human hematopoietic stem cells injected into the liver |
293EBV
+ and
293EBVdelta (BPLF1-KO) |
2015 | BPLF1 contributes to EBV oncogenicity. | 70 |
| NSG+purified human
cord blood CD34-positive hematopoietic stem cells injected into the liver |
B95-8 | 2015 | EBV-associated Hodgkin’s lymphoma develops
exclusively in mice with activated T-cell conditions and EBV-associated non-Hodgkin’s lymphoma develops in mice with a largely suppressed T-cell condition predominantly characterized with an abundance of immature B cells. |
71 |
| NSG-A2tg +purified human
cord blood CD34-positive hematopoietic stem cells injected into the liver |
B95-8 BAC, EBER1
or EBER2 deletion mutants, and revertant viruses |
2015 | Wild-type and EBER-deleted mutant viruses
demonstrate equal ability to persist in vivo. |
72 |
| NSG+purified human fetal liver
CD34-positive hematopoietic stem cells injected into the liver |
B95-8 GFP + | 2015 | The human SAP-dependent 2B4 receptor is required for
CD8 + T cell-mediated control of EBV infection. |
73 |
| NSG+purified CD34-positive
cells from individual fetal liver samples and fetal thymus from the same donor |
p2089 B95-8 BAC
and p2089 B95-8 BAC LMP1-KO |
2015 | LMP1 is not essential for EBV-induced lymphomas
in vivo, and T cells supply signals that substitute for LMP1 in EBV-positive B-cell lymphomagenesis. |
74 |
| NSG-A2tg +purified human
cord blood CD34-positive hematopoietic stem cells injected into the liver |
Wild-type B95-8 and
BZLF1 knockout |
2014 | T cells specific for the lytic EBV antigen BMLF1 can
effectively control lytically replicating EBV + B cells in vivo. |
75 |
| Rag2
−/− γC
−/− double
knockout+human peripheral blood mononuclear cells (PBMCs) or Vγ9Vδ2-T cell- depleted PBMCs |
B95-8 and
B95.8EBfaV- GFP |
2014 | Vγ9Vδ2-T cells contribute to EBV immunity. | 76 |
| NSG+purified CD34-positive
human cord blood mononuclear cells |
B95-8 | 2014 | CD4
+ T cells are necessary for the generation/
maintenance of cells with latency I/IIa phenotype in humanized mice and contribute to this process through expression of CD40L. |
77 |